logo
Sexually transmitted infections returning to pre-pandemic levels in Rhode Island

Sexually transmitted infections returning to pre-pandemic levels in Rhode Island

Yahoo21-04-2025
A colorized electron micrograph shows Treponema pallidum, the bacteria that cause syphilis. The inset shows a closeup of a single strand. (Image by National Institute of Allergy and Infectious Diseases)
HIV and other sexually transmitted infections (STIs) appear to be a slowly rising tide in the Ocean State, according to the most recent data from the state health department.
STI surveillance data is reported on a lag, so the March report issued by the Rhode Island Department of Health (RIDOH) contains long- and short-term data ending in 2023, plus some tentative findings for 2024. But recent increases in infections could also be trends returning to their baseline prior to the pandemic.
'If you look at the data starting in 2020 we did see some significant declines starting with the pandemic, and that is because we were seeing less testing, less healthcare visits,' said Dr. Philip Chan, a primary care physician with Brown University Health and a medical consultant on the RIDOH report.
But people's behavior also changed during that time, Chan added. 'People were more likely to stay at home, more likely to isolate. What we were seeing on the ground was that a lot of people had a lot less sex partners, so there was just a lot less sex going on.'
The good news is that the state usually succeeds in treating HIV, with outcomes more positive than national averages and patients' illness often stops before the virus progresses into AIDS. Less ideal are higher rates for other STIs like syphilis and gonorrhea, which climbed past pre-pandemic levels in 2023.
'From year to year, it's tough to tell exactly what's happening,' Chan said. 'But I think that the trends the last couple years are clear that things are going up.'
Data for the more ubiquitous infections includes:
Syphilis has increased 58% from 2014 to 2023. There were 328 cases recorded in 2021, the highest number in decades. That fell to 240 cases in 2022, and 190 in 2023 — about the same as pre-pandemic levels, which had already risen since 2014. Preliminary data for 2024 shows similar trends. From 2020 to 2023, there were also about 10 cases of congenital syphilis — the state's first instances in about a decade, and one example of testing's importance in early detection, Chan said.
Gonorrhea cases rose 183.4% over the last 10 years. There were 590 cases in 2014, compared to 1,672 cases in 2023. There has not been a year with fewer than 1,000 cases since 2016. Men account for about twice as many cases as women.
Chlamydia cases have remained more consistent since 2014, and rose 21% over the decade, from 4,349 cases in 2014 to 5,269 cases in 2023. Women ages 20-24 exhibited the highest increase over that same period, but the report notes that women access routine screenings more than men, who are often asymptomatic when infected.
'A key theme for all these STIs is that most people may not have symptoms,' Chan said. 'And so the only way that you know that you may have it is to get tested, and that's why testing is so so important.'
Chan pointed to primary care doctors and sex education as two ways people can become educated about the necessity of screening. Only 52% of adults ages 18 to 64 who had multiple sex partners received an STI test in the past year, according to 2022 data. Only 60% had ever received an HIV test.
What we were seeing on the ground was that a lot of people had a lot less sex partners, so there was just a lot less sex going on.
– Dr. Philip Chan, primary care physician and medical consultant for RIDOH STI surveillance report
Demographic and geographic factors also shaped the data. Racial disparities exist: In 2023, HIV rates were four times higher among Black residents and nearly sevenfold higher among Rhode Island's Latino population, compared to caucasian residents. New HIV cases among Latinos have risen 132% since 2019, while dropping 63% among Black Rhode Islanders. Of newly diagnosed HIV cases in 2023, 31% were diagnosed in people born outside the United States, most frequently in the Caribbean and Central and South America.
Younger people ages 15-24 account for most new STI diagnoses, about half. The state's urban core of Providence, East Providence, North Providence, Pawtucket, Woonsocket, Central Falls, and Cranston consistently reports the highest STI rates, with cases numbering in the dozens to hundreds, compared to fewer than five reported cases in many smaller towns.
'A lot of these STIs do disproportionately affect communities of color and other sorts of underserved populations,' Chan said. 'It's important, from a public health perspective, to think about how to continue and promote and increase access to care for those groups in order to address disparities like we see in STIs and frankly, many other things.'
While an assortment of drugs can stop bacterial infections, there's no cure for HIV. But HIV-positive people are living longer than ever due to modern antiretroviral drugs that suppress the virus and prevent it from progressing to a more serious diagnosis of AIDS. An adequately suppressed viral load can also make the disease intransmissible, and greatly improves quality of life by halting the virus from replicating. Advances in HIV drug therapy largely account for the deep reduction in the rate of HIV-related deaths, which nationally fell by almost half from from 2010 to 2017.
In Rhode Island in 2022, 93.2% of people living with HIV knew their status, 76% were receiving treatment and 71% had achieved viral suppression. And 93% of people who received their medical care within Rhode Island achieved viral suppression.
Still, there was an above average number of HIV diagnoses, the preliminary 2024 data showed. From 2019-2023, RIDOH also observed that about 20% of people newly diagnosed with HIV had progressed to stage 3, or AIDS. On average, it takes eight years for HIV to develop into AIDS.
Rhode Island has tried to prevent those outcomes by early diagnosis, and by fortifying its residents against HIV through preventative measures — namely, PrEP, or pre-exposure prophylaxis. Patients who adhere to the schedule for taking this group of antiretroviral drugs can have up to a 99% lower chance of contracting HIV from unprotected sex. PrEP provides an approximate 74% reduction in the likelihood of contracting HIV via injectable drug use.
Successful state laws from 2023 and 2024 made PrEP as widely available as possible by slashing away potential restrictions from insurers and eliminating out-of-pocket costs. Chan, only had 'good things to say' about those laws — including the resulting interactions with insurers, who have largely been quick to correct mistakes in patient billing. The main challenge now, Chan said, is when interruptions occur, and a person loses their job, insurance, and access to PrEP.
Several sexual health clinics and community health centers in Rhode Island offer low or no cost services and assist in minimizing any out-of-pocket costs associated with PrEP prescriptions and testing. For a list go to Rhode Island's PrEP Champions Network.
'I actually had a patient of mine for several years who had insurance and was on PrEP,' Chan said. 'They lost their insurance for a couple months and had to go off PrEP, and they actually, unfortunately, acquired HIV during that time. This was just a month ago.'
RIDOH continues to promote the Rhode Island PrEP Champions Network, which has participating clinics across the state that expedite access to PrEP as well as its sibling PEP, or post-exposure prophylaxis, which is taken for about a month, starting within 72 hours of possible HIV exposure. Properly taken, the drug prevents HIV infection.
The comparable treatment for preventing bacterial STIs is DoxyPEP, which usually consists of a single, two-pill, dose of doxycycline taken after sex. Doxycycline is an old drug, and thus an inexpensive means of lowering contraction rates, Chan suggested.
'DoxyPEP is the newest kid on the block,' he said, noting that the nationwide rollout is still in its early stages. But so far the data looks good, with evidence from places like San Francisco suggesting it can make a difference.
'We're very optimistic about it, and I think the coming years will be able to tell whether or not it's making a significant impact on overall population trends,' Chan said.
SUBSCRIBE: GET THE MORNING HEADLINES DELIVERED TO YOUR INBOX
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Small Investment, Big Returns: Why This NIH Center Matters
Small Investment, Big Returns: Why This NIH Center Matters

Forbes

time33 minutes ago

  • Forbes

Small Investment, Big Returns: Why This NIH Center Matters

UNITED STATES - MAY 10: Activists hold signs during rally outside the National Institutes of Health in Bethesda, Md., on Saturday, May 10, 2025. (Bill Clark/CQ-Roll Call, Inc via Getty Images) CQ-Roll Call, Inc via Getty Images 25 years ago, I had a life-changing experience. I got the biggest break in my career. My application to do a PhD at the University of California, Berkeley was accepted, and I was offered funding support through a National Institutes of Health (NIH) program called the Fogarty AIDS International Training Program. I had little money those days, and without NIH funding and a welcoming professor who cared deeply about global health, I could have never left India for higher education in the United States. Today, I chair a department of global and public health at a leading Canadian university. The life-changing opportunities I had as a Fogarty trainee at Berkeley allow me to pay it forward by training the next generation of global health leaders. I was not the only scholar to benefit from Fogarty funding - nearly 8,500 individuals from 132 countries have trained through Fogarty programs since 1989, and many have become leaders in their countries. Several have led groudbreaking research projects, and led inspiring programs and institutions. Soumya Swaminathan is a great example. After her Fogarty training in the United States, she went on to become a leading HIV and TB researcher, become the Director-General of the Indian Council of Medical Research, and subsequently the first Chief Scientist of the World Health Organization. 'My Fogarty fellowship gave me an opportunity to get exposed to advanced immunological techniques and meet leading experts at a critical stage of my career. It helped spark new ideas and initiate collaboration with international experts which may not have happened otherwise,' she said. Another shining example is Glenda Gray, who was the first female President of the South African Medical Research Council. 'Becoming a Fogarty Fellow catalysed my career as a clinician scientist, and marked the beginning of my research trajectory," she said. "It enabled me to make contributions to HIV vaccine research and development, as well as research in the area of preventing mother to child transmission. The interventions we developed have led to the control of paediatric HIV and improvements in treatment that have reduced HIV-related mortality in children,' she explained. Gray is currently Director of the Infectious Disease and Oncology Research Institute, University of the Witwatersrand. The Fogarty International Center (FIC) has also benefitted US scientists and institutions. In FY24, Fogarty funded 440 U.S. grantees from 122 U.S. institutions in 39 states. Research conducted in Global South countries have led to improved treatments for health challenges of importance to Americans. 'The training programs supported by the FIC over the past 40 years have been unparalleled in their reach and impact around the world,' said Arthur Reingold, Emeritus professor at Berkeley School of Public Health, who has trained hundreds of scholars through his Fogarty grants. 'They have, through their support of highly talented biomedical scientists from scores of low and middle income countries, dramatically improved research and educational capacity globally, as well as markedly enhanced high impact collaborative research on AIDS, tuberculosis, malaria, and diverse other communicable and non communicable diseases. The benefits resulting from the enhanced research capabilities of scientists supported by the FIC have accrued to people living everywhere, including in the United States,' he elaborated. Lucian Davis, an Associate Professor at Yale Medicine and the Yale School of Public Health, has also used the Fogarty program to train dozens of American and African scholars. 'Fogarty enables us to train the world's brightest minds to tackle America's leading health priorities—a high-impact, low-cost investment that keeps us connected to the world,' he said. And guess what, the entire annual budget of the FIC is a merely 0.2% of the total NIH budget - a drop in the bucket. Despite this tiny investment, the FIC has had a spectacular national and global footprint and impact, by any metric. Today, it greatly saddens me to see defunding of US science agencies, including NIH, and it's devastating impact on US academic institutions and scientists. Several American scientists have either reached out to me to explore options in Canada, or have applied for faculty positions at my university. Scores of American scientists are seeking to flee the country (and become "science refugees"). It boggles my mind that US politicians are allowing this brain drain to happen under their watch. America's economic strength, in part, comes from the nation's immense scientific firepower. I am especially distressed to learn that the FIC is once again on the chopping block, with the entire $95 million budget FIC budget set to become zero in 2026. How exactly is cutting such an impactful program supposed to make America great? Even as the world deals with massive crises like pandemics, conflicts, climate change, and widening economic inequities, all of which require truly, global cooperation and coordination, it seems like politicians are choosing narrow self-interests, nationalism, and isolationism. This strategy is not likely to succeed. Why? We've all witnessed how interconnected the world is during the Covid-19 pandemic. Viruses that emerge in far away places will find us, regardless of who we are or where we happen to live. Every outbreak is merely one long-haul flight away. Smoke from wildfires will travel thousands of miles to darken our skies and choke our lungs. NEW YORK, NEW YORK - JUNE 7: Smoky haze from wildfires in Canada diminishes the visibility of the Chrysler Building on June 7, 2023 in New York City. (Photo by David) Getty Images There is no way to protect just one nation or one region when threats are trans-national. Our fates are undisputably intertwined with that of other countries and peoples. There is nothing 'woke' about looking out for each other in an interdependent world. And that is why America must stay engaged in global health and multi-laterialism. And that is why American lawmakers must work to protect a national treasure like the Fogarty International Center. If an investment is yielding spectacular returns, no smart business person would dream of killing it. So, why defund the FIC and the NIH? If I was a US lawmaker, that is the question I would be asking myself. I take some hope from the fact that the Senate Appropriations Committee recently rejected the Trump administration's proposed funding cuts to the NIH. But the road ahead is long and hard. I hope good sense will prevail and the powers that be will find a way to save America's phenomenal scientific enterprise. Science matters for America's health. It matters for health of the whole world.

Trump previously called mRNA vaccines a 'medical miracle.' Now, RFK Jr. cut $500M in funding

time5 hours ago

Trump previously called mRNA vaccines a 'medical miracle.' Now, RFK Jr. cut $500M in funding

When the Pfizer-BioNTech COVID-19 vaccine was authorized for emergency use by the Food and Drug Administration (FDA) in December 2020, President Donald Trump referred to it as a "medical miracle." "This is one of the greatest scientific accomplishments in history. It will save millions of lives and soon end the pandemic once and for all," Trump said at the time in a speech delivered from the Oval Office. COVID-19 vaccines, made with mRNA technology, were quickly rolled out with then-Health and Human Services Secretary Alex Azar referring to the vaccine as "safe and extraordinarily effective." However, last week, current Health Secretary Robert F. Kennedy Jr. announced that the government was canceling at least $500 million of federally funded mRNA vaccine development, potentially affecting U.S. preparedness for future pandemics and squashing enthusiasm for technology that has been hailed as a potential promise for cancer and HIV vaccines. Public health experts told ABC News the position Kennedy and those in his circle have taken on mRNA vaccines is very different from how the technology was viewed in the Trump administration during the president's first term. "The president was absolutely right when he called mRNA vaccines a miracle," Dr. Richard Besser, president and CEO of the Robert Wood Johnson Foundation and former acting director of the Centers for Disease Control and Prevention during the Obama administration, told ABC News. "It was absolutely miraculous that in under a year after a new infectious agent hit the world stage, we had multiple safe and highly effective vaccines to protect people. … What we have now is a situation where the Trump administration is backing away from mRNA technology," Besser said. "It is totally out of line with what the president was saying during his first term, and it flies in the face of what science and evidence have demonstrated." Praise for mRNA vaccines In the early days of the COVID-19 pandemic, when the majority of Americans were masking and following stay-at-home orders, the Trump administration launched Operation Warp Speed in May 2020. The goal of the public-private partnership, initiated by the U.S. government, was to help accelerate the development, testing, manufacturing and distribution of COVID-19 vaccines, therapeutics and diagnostics. From more than 100 vaccine candidates, the government narrowed it down to fewer than 10 to receive funding for development and testing Although mRNA was discovered in 1961, breakthroughs in developing mRNA vaccines began in the early 2000s, eventually leading to the development of COVID-19 vaccines in 2020. During the COVID-19 pandemic, mRNA technology demonstrated its ability to scale up vaccine production quickly, as seen with the Pfizer and Moderna vaccines. Public health officials in the Trump administration expressed enthusiasm for the vaccines. Just before the Moderna COVID-19 vaccine received emergency use authorization from the FDA, Azar referred to the shot as "exceptionally safe" and "shockingly effective." Meanwhile, then-Surgeon General Dr. Jerome Adams encouraged Americans to get vaccinated, saying, "By golly, the finish line is in sight. So, we just got to keep on running. American people, we need you to keep on running." Additionally, in December 2020, during a virtual conversation hosted by the University of Tennessee Health Science Center, then-CDC director Dr. Robert Redfield said the mRNA COVID-19 vaccines were "extremely safe" and were a "light at the end of the tunnel." "It is no longer a scientific problem, but whether we can get the population vaccinated," he said at the time. "We're in a fight and what we need now is unity of spirit and to let data and science drive our actions." In a further show of support, several of the nation's top public health officials received a COVID-19 vaccine publicly to demonstrate its safety and effectiveness including Azar; Dr. Francis Collins, then-director of the National Institutes of Heath; Dr. Anthony Fauci, then-director of NIH's National Institute on Allergy and Infectious Diseases (NIAID); and Colleen McGowan, director of NIH's Office of Research Services. Trump's public health officials continued to express support for Operation Warp Speed and mRNA technology even after leaving office. In December 2022, during a seminar at the University of Pennsylvania, Azar referred to Operation Warp Speed as "my biggest achievement at HHS and in my life." He explained how scientists in China posted a genetic sequence online of SARS-CoV-2, the virus that causes COVID-19, on Jan. 10, 2020, and, three days later, NIAID scientists had developed a seed vaccine, a sample used as the starting material for vaccine production. "Then they partnered that with Moderna, with whom we had already been working with on mRNA technology for about a decade," Azar said. "We partnered with them and eight weeks later were in human trials. It was the fastest time in human history that a [pharmaceutical] product has moved from discovery to actual phase one human trials." Retreat from mRNA vaccines In Trump's second term, the nation's top public health officials seem to have a different opinion of mRNA vaccines. Kennedy had already been expressing vaccine-skeptic views before becoming health secretary. In May 2021, he filed a citizen petition asking for the federal government to revoke its authorization of all COVID-19 vaccines. In December 2021, during a Louisiana House of Representatives meeting discussing a proposal to require schoolchildren to receive the COVID-19 vaccine, Kennedy falsely called the vaccine the "deadliest vaccine ever made." Since becoming health secretary, Kennedy made a series of moves, including announcing earlier this year that the COVID-19 vaccine will no longer be recommended for healthy children and healthy pregnant women. In a press release announcing the cancellation of mRNA vaccine funding, Kennedy said that funding was going towards "safer, broader vaccine platforms that remain effective even as viruses mutate," despite infectious disease experts and vaccinologists saying the mRNA platform is safe. Kennedy also falsely claimed mRNA vaccines can prolong pandemics. When asked about the cancellation of funding by reporters, Trump praised Operation Warp Speed but said it was "a long time ago, and we're onto other things" and that the administration is "looking for other answers to other problems, to other sicknesses and diseases." Additionally, over the weekend, during an appearance on Steve Bannon's podcast "War Room," NIH director Dr. Jay Bhattacharya said Kennedy decided to cancel mRNA vaccine contracts because "the mRNA platform is no longer viable." He also claimed a large fraction of the public doesn't trust the platform for vaccines. Dr. Craig Spencer, an associate professor of the practice of health services, policy and practice at Brown University School of Public Health, said it seems strange that Operation Warp Speed no longer gets the praise it once received during Trump's first term. "I find it so remarkable that really the biggest accomplishment of the end of Trump's first term in office … namely the creation of Operation Warp Speed in the mRNA vaccines is something that this administration truly never talks about," Spencer told ABC News. "The second Trump administration never talks about. In fact, he somehow went from leaving office as the person that helped create Operation Warp Speed, saving millions of lives in the U.S. and tens of millions of lives, if not more, around the world, to putting in place someone who is an ardent vaccine cynic." Some public health officials from Trump's first term have since flipped their stance on vaccines. Redfield, the former CDC director, said in a POLITICO event earlier this year that in his practice, he's seen patients with "very serious long-term consequences from the mRNA vaccines." Others condemned Kennedy's decision to cut mRNA funding. Former U.S. Surgeon General Adams calling it "dangerous" and saying that risks "far outweigh rare side effects." Spencer said there is a difference in the way that Adams speaks about vaccines compared to Trump's current nominee for U.S. surgeon general, Dr. Casey Means, a prominent voice in Kennedy's "Make America Healthy Again" movement. Means has not made a public statement on Kennedy's recent decision, but she has expressed skepticism about the safety of childhood vaccines and has called for more research on the "safety of the cumulative effects" of vaccines. "Jerome Adams probably knows the difference between what [COVID] looks like at the clinical level because he is someone that has practiced as an anesthesiologist, has seen the sickest patients and continues to practice," he told ABC News. "He knows, as a practicing physician, what this will mean, as opposed to sharing viewpoints from a book about wellness and anti-vaccine views." "I have not seen the new Surgeon General take a perspective on what has been taking place around vaccination," Besser added. "I would hope that she would do what's right by the American people and encourage people to be vaccinated fully and on time."

Trump's Ex-Surgeon General Attacks Vaccine Cuts: 'People Are Going To Die'
Trump's Ex-Surgeon General Attacks Vaccine Cuts: 'People Are Going To Die'

Newsweek

timea day ago

  • Newsweek

Trump's Ex-Surgeon General Attacks Vaccine Cuts: 'People Are Going To Die'

Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. President Donald Trump's former Surgeon General Jerome Adams has warned that "people are going to die" if the United States cuts funding for mRNA vaccine development. It comes after Health and Human Services Secretary Robert F. Kennedy Jr. announced last week that his department would terminate 22 Biomedical Advanced Research and Development Authority (BARDA) investments in mRNA vaccine development, representing nearly $500 million in federal funding. He said the decision was taken after reviews showed mRNA vaccines "failed protect effectively against upper respiratory infections like COVID and flu." Newsweek contacted the United States Department of Health and Human Services (HHS) for comment via email outside of regular working hours. Former Surgeon General Jerome Adams speaking at the White House in April 2020. Former Surgeon General Jerome Adams speaking at the White House in April 2020. AP Why It Matters Kennedy has been a longtime vaccine critic, and questioned their effectiveness on numerous occasions. His tenure as the head of HHS has seen top vaccine experts, food safety supervisors and other public-health officials either resign or be ousted. The 22 projects are led by major pharmaceutical companies, including Pfizer and Moderna, and aim to develop vaccines against the flu, COVID-19 and H5N1. mRNA technology, which underpins these vaccines, is widely credited with helping slow the spread of the coronavirus during the 2020 pandemic. Infectious-disease specialists have also warned that future pandemics will be harder to stop without the help of mRNA. What To Know Adams, who served in Trump's first administration, said in an interview with CBS News on Sunday that mRNA technology accelerated vaccine development by an estimated 18 to 24 months. He added that "by the most conservative estimates, at least 2 million lives were saved" during the pandemic because of mRNA vaccines. "It's a natural molecule that's in all of our bodies. It's like a recipe card that tells your body how to make a protein," he said. "And this new idea, again, helps us develop vaccines and new treatments for everything from cancer, melanoma - which my wife has - to HIV, to better flu vaccines." He added: "These are advances that are not going to happen now... people are going to die because we're cutting short funding for this technology." Several other infectious disease experts have also spoken out against Kennedy's decision. Rick Bright, the former director of BARDA, said on X: "A bad day for science, and huge blow to our national security. This decision will have dangerous repercussions." Dr. Thomas A. Russo, an expert in infectious diseases, told Newsweek that Kennedy's decision was "shortsighted," and said mRNA vaccines "will be critical when the next, inevitable infectious diseases crisis rears its ugly head." What People Are Saying RFK Jr. said on X last week: "We reviewed the science, listened to the experts, and acted. BARDA is terminating 22 mRNA vaccine development investments because the data show these vaccines fail to protect effectively against upper respiratory infections like COVID and flu." Infectious diseases expert Dr. Amesh Adalja, a senior scholar at the Johns Hopkins Center for Health Security, who specializes in pandemic preparedness, told Newsweek: "RFK's actions are completely devoid of value. They are only designed to serve more distrust of a proven and valuable vaccine technology. The repercussions of this decision will serve only to diminish the resiliency of the United States, and the world, to infectious disease threats." What Happens Next In his statement, Kennedy urged the department to shift from mRNA vaccines and "invest in better solutions," but did not specify alternatives. Lawmakers, public-health officials, and industry leaders are expected to press HHS for detailed timelines and alternative research investments options.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store